A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis

2010989 citationsJournal Articlebronze Open Access

Authors

Gavin Giovannoni · Queen Mary University of London

Gıancarlo Comı · Vita-Salute San Raffaele University

Stuart D. Cook · Rutgers New Jersey Medical School

Kottil Rammohan · The Ohio State University

Peter Rieckmann · Vancouver Coastal Health

Per Soelberg Sørensen · Copenhagen University Hospital

Patrick Vermersch

Abstract

Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)

Topics & Keywords

Multiple Sclerosis Research Studies Chronic Lymphocytic Leukemia Research Peripheral Neuropathies and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 5, pp. 416-426

DOI: 10.1056/nejmoa0902533

Field-Weighted Citation Impact: 47.53